Literature DB >> 22234629

Maintenance therapy for first-line metastatic colorectal cancer: activity and sustainability.

John H Strickler1, Herbert I Hurwitz.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22234629      PMCID： PMC3267828          DOI： 10.1634/theoncologist.2011-0358

Source DB:  PubMed          Journal:  Oncologist        ISSN： 1083-7159


× No keyword cloud information.
  4 in total

1.  OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer--a GERCOR study.

Authors:  Christophe Tournigand; Andres Cervantes; Arie Figer; Gérard Lledo; Michel Flesch; Marc Buyse; Laurent Mineur; Elisabeth Carola; Pierre-Luc Etienne; Fernando Rivera; Isabel Chirivella; Nathalie Perez-Staub; Christophe Louvet; Thierry André; Isabelle Tabah-Fisch; Aimery de Gramont
Journal:  J Clin Oncol       Date:  2006-01-20       Impact factor: 44.544

2.  First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: the phase III MACRO TTD study.

Authors:  Eduardo Díaz-Rubio; Auxiliadora Gómez-España; Bartomeu Massutí; Javier Sastre; Albert Abad; Manuel Valladares; Fernando Rivera; Maria J Safont; Purificación Martínez de Prado; Manuel Gallén; Encarnación González; Eugenio Marcuello; Manuel Benavides; Carlos Fernández-Martos; Ferrán Losa; Pilar Escudero; Antonio Arrivi; Andrés Cervantes; Rosario Dueñas; Amelia López-Ladrón; Adelaida Lacasta; Marta Llanos; Jose M Tabernero; Antonio Antón; Enrique Aranda
Journal:  Oncologist       Date:  2012-01-10

3.  Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 Study.

Authors:  Benoist Chibaudel; Frédérique Maindrault-Goebel; Gérard Lledo; Laurent Mineur; Thierry André; Mostepha Bennamoun; May Mabro; Pascal Artru; Elisabeth Carola; Michel Flesch; Olivier Dupuis; Philippe Colin; Annette K Larsen; Pauline Afchain; Christophe Tournigand; Christophe Louvet; Aimery de Gramont
Journal:  J Clin Oncol       Date:  2009-09-28       Impact factor: 44.544

4.  Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200.

Authors:  Bruce J Giantonio; Paul J Catalano; Neal J Meropol; Peter J O'Dwyer; Edith P Mitchell; Steven R Alberts; Michael A Schwartz; Al B Benson
Journal:  J Clin Oncol       Date:  2007-04-20       Impact factor: 44.544
  4 in total
  3 in total

1.  MODUL-a multicenter randomized clinical trial of biomarker-driven maintenance therapy following first-line standard induction treatment of metastatic colorectal cancer: an adaptable signal-seeking approach.

Authors:  Hans-Joachim Schmoll; Dirk Arnold; Aimery de Gramont; Michel Ducreux; Axel Grothey; Peter J O'Dwyer; Eric Van Cutsem; Frank Hermann; Ivan Bosanac; Belguendouz Bendahmane; Christoph Mancao; Josep Tabernero
Journal:  J Cancer Res Clin Oncol       Date:  2018-04-11       Impact factor: 4.553

2.  Chemotherapy re-challenge response rate in metastatic colorectal cancer.

Authors:  Alexandra E Chambers; Jacob Frick; Natalee Tanner; Richard Gerkin; Madappa Kundranda; Tomislav Dragovich
Journal:  J Gastrointest Oncol       Date:  2018-08

3.  Maintenance treatment with the immunomodulator MGN1703, a Toll-like receptor 9 (TLR9) agonist, in patients with metastatic colorectal carcinoma and disease control after chemotherapy: a randomised, double-blind, placebo-controlled trial.

Authors:  Hans-Joachim Schmoll; Burghardt Wittig; Dirk Arnold; Jorge Riera-Knorrenschild; Dieter Nitsche; Hendrik Kroening; Frank Mayer; Johannes Andel; Reinhard Ziebermayr; Werner Scheithauer
Journal:  J Cancer Res Clin Oncol       Date:  2014-05-10       Impact factor: 4.553
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.